410 related articles for article (PubMed ID: 22894572)
1. Quality-of-life effects of prostate-specific antigen screening.
Heijnsdijk EA; Wever EM; Auvinen A; Hugosson J; Ciatto S; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Zappa M; Tammela TL; Mäkinen T; Carlsson S; Korfage IJ; Essink-Bot ML; Otto SJ; Draisma G; Bangma CH; Roobol MJ; Schröder FH; de Koning HJ
N Engl J Med; 2012 Aug; 367(7):595-605. PubMed ID: 22894572
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
3. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
Carlsson SV; de Carvalho TM; Roobol MJ; Hugosson J; Auvinen A; Kwiatkowski M; Villers A; Zappa M; Nelen V; Páez A; Eastham JA; Lilja H; de Koning HJ; Vickers AJ; Heijnsdijk EA
Cancer; 2016 Nov; 122(21):3386-3393. PubMed ID: 27459245
[TBL] [Abstract][Full Text] [Related]
4. Screening for prostate cancer.
Ilic D; Neuberger MM; Djulbegovic M; Dahm P
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
[TBL] [Abstract][Full Text] [Related]
5. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
6. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
7. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme.
Boniol M; Boyle P; Autier P; Ruffion A; Perrin P
BJU Int; 2012 Dec; 110(11):1648-52. PubMed ID: 22984785
[TBL] [Abstract][Full Text] [Related]
8. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.
de Koning HJ; Gulati R; Moss SM; Hugosson J; Pinsky PF; Berg CD; Auvinen A; Andriole GL; Roobol MJ; Crawford ED; Nelen V; Kwiatkowski M; Zappa M; Luján M; Villers A; de Carvalho TM; Feuer EJ; Tsodikov A; Mariotto AB; Heijnsdijk EAM; Etzioni R
Cancer; 2018 Mar; 124(6):1197-1206. PubMed ID: 29211316
[TBL] [Abstract][Full Text] [Related]
10. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.
Gulati R; Mariotto AB; Chen S; Gore JL; Etzioni R
J Clin Epidemiol; 2011 Dec; 64(12):1412-7. PubMed ID: 22032753
[TBL] [Abstract][Full Text] [Related]
11. Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial.
Martin RM; Donovan JL; Turner EL; Metcalfe C; Young GJ; Walsh EI; Lane JA; Noble S; Oliver SE; Evans S; Sterne JAC; Holding P; Ben-Shlomo Y; Brindle P; Williams NJ; Hill EM; Ng SY; Toole J; Tazewell MK; Hughes LJ; Davies CF; Thorn JC; Down E; Davey Smith G; Neal DE; Hamdy FC;
JAMA; 2018 Mar; 319(9):883-895. PubMed ID: 29509864
[TBL] [Abstract][Full Text] [Related]
12. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
13. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.
Draisma G; Etzioni R; Tsodikov A; Mariotto A; Wever E; Gulati R; Feuer E; de Koning H
J Natl Cancer Inst; 2009 Mar; 101(6):374-83. PubMed ID: 19276453
[TBL] [Abstract][Full Text] [Related]
14. Results of the spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Update after 21 years of follow-up.
Luján Galán M; Páez Borda Á; Llanes González L; Romero Cajigal I; Berenguer Sánchez A
Actas Urol Esp (Engl Ed); 2020; 44(6):430-436. PubMed ID: 32147352
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
17. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.
Schröder FH; Hugosson J; Roobol MJ; Tammela TL; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Määttänen L; Lilja H; Denis LJ; Recker F; Paez A; Bangma CH; Carlsson S; Puliti D; Villers A; Rebillard X; Hakama M; Stenman UH; Kujala P; Taari K; Aus G; Huber A; van der Kwast TH; van Schaik RH; de Koning HJ; Moss SM; Auvinen A;
Lancet; 2014 Dec; 384(9959):2027-35. PubMed ID: 25108889
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis.
Ilic D; Djulbegovic M; Jung JH; Hwang EC; Zhou Q; Cleves A; Agoritsas T; Dahm P
BMJ; 2018 Sep; 362():k3519. PubMed ID: 30185521
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC).
Roobol MJ; Kerkhof M; Schröder FH; Cuzick J; Sasieni P; Hakama M; Stenman UH; Ciatto S; Nelen V; Kwiatkowski M; Lujan M; Lilja H; Zappa M; Denis L; Recker F; Berenguer A; Ruutu M; Kujala P; Bangma CH; Aus G; Tammela TL; Villers A; Rebillard X; Moss SM; de Koning HJ; Hugosson J; Auvinen A
Eur Urol; 2009 Oct; 56(4):584-91. PubMed ID: 19660851
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
